Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer

Cancer Journal

Volumn 13, Issue 4, 2007, Pages 257-262

  Burtness, Barbara ^a   Thomas, Laurie ^b   Sipples, Rebecca ^c   McGurk, Meghan ^c   Salikooti, Saritha ^d   Christoforou, Maryanne ^e   Mirto, Gayle ^a   Salem, Ronald ^c   Sosa, Julieann ^c   Kloss, Robert ^f   Rahman, Zia ^b   Chung, Gina ^b   Lacy, Jill ^b   Murren, John R ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b YALE CANCER CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NASSAU UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f DANBURY HOSPITAL   (United States)

Author keywords

Clinical trials; Docetaxel; Irinotecan; Pancreatic cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CA 19-9 ANTIGEN; CREATININE; DEXAMETHASONE; DOCETAXEL; IRINOTECAN; LOPERAMIDE; LOW MOLECULAR WEIGHT HEPARIN; THROMBOCYTE CONCENTRATE; WARFARIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; TAXOID;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD LEVEL; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CREATININE CLEARANCE; DIABETES MELLITUS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ERYTHROCYTE CONCENTRATE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERGLYCEMIA; INFECTION; LUNG EMBOLISM; MALE; METASTASIS; NAUSEA AND VOMITING; NEUTROPENIA; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; RECURRENT DISEASE; SCREENING; SURVIVAL RATE; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TUMOR BIOPSY; ADENOCARCINOMA; DISEASE COURSE; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; THROMBOSIS;

EID: 35748979171     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31813c1174     Document Type: Article

References (26)

1. Cancer Facts and Figures, 2007. American Cancer Society. Available at: www.cancer.org. Accessed July 6, 2007.
2. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15: 2403-2413.
3. Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003;21:3402-3408.
4. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J Clin Oncol. 2002;20:3270-3275.
5. Colucci G, Giulani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia del l'Italia Meridionale. Cancer. 2002; 94:902-910.
6. Louvet C, Labianca R, Hammel P, et al. GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in non resectable pancreatic adenocarcinoma: Final results of the GERCOR/GISCAD Intergroup Phase III. J Clin Oncol. 2004;22(14 Suppl):4008.
7. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). J Clin Oncol. 2007;25:1960-1966.
8. Lenzi R. Yalcin S. Evans DB, et al. Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Invest. 2002;20:464-472.
9. Rougier P, Adenis A, Ducreux M, et al. Phase II study of docetaxel as first line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer. 2000;36:1016-1025.
10. Wagener DJ, Verdonk HE, Dirix LY, et al. Phase II trial of CPT11, irinotecan hydrochloride, in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol. 1995;6:129-132.
11. Bissery MC, Vrignaud P, Lavelle F. In vivo evaluation of the docetaxelirinotecan combination (abstract 2578). Proc Am Assoc Cancer Res. 1996;37:378.
12. Pei XH, Nakanishi Y, Takayama K, et al. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anti-cancer Drugs. 1997;8:231-237.
13. Kano Y, Akutsu M, Tsunoda S, et al. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines. Cancer Chemother Pharmacol. 1998;42:91-98.
14. Bleickardt E, Argiris A, Rich R, et al. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer. Cancer Biol Ther. 2002;1:646-650.
15. Adjei AA, Klein CE, Kastrissios H, et al. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors preliminary evidence of clinical activity. J Clin Oncol. 2000;18:1116-1123.
16. Couteau C, Risse M-L, Ducreux M, et al. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors. J Clin Oncol. 2000;18:3545-3552.
17. Abigerges D, Armand JP, Chabot GG, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst. 1994;86:446-449.
18. WHO Handbook for Reporting Results of Cancer Treatment. Offset Geneva, Switzerland: World Health Organization, 1979. Offset Publication No. 48.
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
21. Richards DA, Kindler HL, Oettle H, et al. A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. J Clin Oncol 2004;22 (14 Suppl):4007.
22. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22: 3776-3783.
23. Reni M, Cordio S, Milandra C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005;6:369-376.
24. Reni M, Panucci MG, Passoni P, et al. Salvage chemotherapy with mitomycin, docetaxel and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial. Cancer Invest. 2004;22: 688-696.
25. Sørensen HT, Mellemkjœr L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343: 1846-1850.
26. Roselli M, Mineo TC, Basili S, et al. Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. Thromb Haemost. 2003;89: 177-184.